Talisman Therapeutics Limited
Mark Treherne is an accomplished professional with extensive experience in the life sciences sector, currently serving as Chairperson for several companies, including Talisman Therapeutics Limited, Ubiquigent Ltd, Monument Therapeutics, and NuVision Biotherapies Ltd. With a background in pharmacology, including a Ph.D. and M.Phil. from the University of Cambridge, Mark Treherne has held key leadership roles, such as Chief Executive at Cellesce Ltd and Avilex Pharma ApS, and contributed as a Non-Executive Director at Cell Guidance Systems and Domain Therapeutics. Mark Treherne has a proven track record in drug discovery, biotherapeutics, and immuno-oncology, actively driving innovation to address unmet medical needs in various health domains.
This person is not in the org chart
This person is not in any teams
Talisman Therapeutics Limited
Talisman Therapeutics is a human stem cell drug discovery company, based in Cambridge, UK. We are committed to revolutionising the discovery of treatments for Alzheimer’s disease (AD). Our novel human stem cell models of AD provide a transformative platform for rapid and more therapeutically relevant compound identification, thereby offering the potential to significantly accelerate drug discovery and, more importantly, de-risk subsequent development.